in the adjuvant chemotherapy of stage III colon cancer.[8] The metalloid arsenic trioxide relieves the differentiation blockade in acute promyelocytic leukaemia (PML) and achieves high cure rates.[9] It binds to cysteine thiols on the PML‐moiety of the oncogenic fusion protein PML‐RARα, which leads to its degradation.[10] A few examples of metal‐based drugs are in clinical trials, for instance, BOLD‐100 and ferroquine. The gene discussed is PML; the disease is malignant colon neoplasm.